Gene · 780
Papers2,465
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,465
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| In vitro screening methods of novel immune checkpoint inhibitors related to T cell infiltration and anti-PD-1 resistance. | Methods Cell Biol | 2024 | 39515875 | PubTator, text mining | PubMed |
| Mechanosensory entities and functionality of endothelial cells. | Front Cell Dev Biol | 2024 | 39507419 | PubTator, text mining | PubMed |
| [MiR-6838-5p overexpression inhibits proliferation of breast cancer MCF-7 cells by downregulating DDR1 expression]. | Nan Fang Yi Ke Da Xue Xue Bao | 2024 | 39505335 | PubTator, text mining | PubMed |
| Clinical significance of peripheral blood DDR1 and CtBP gene methylation detection in patients with acute pancreatitis. | Epigenetics | 2024 | 39485950 | PubTator, text mining | PubMed |
| Ruminant Trans Fatty Acid Intake Modulates Inflammation Pathways in the Adipose Tissue Transcriptome of C57BL/6 Mice. | Mol Nutr Food Res | 2024 | 39396377 | PubTator, text mining | PubMed |
| CH6824025, Potent and Selective Discoidin Domain Receptor 1 Inhibitor, Reduces Kidney Fibrosis in Unilateral Ureteral Obstruction Mice. | J Pharmacol Exp Ther | 2024 | 39379147 | PubTator, text mining | PubMed |
| The major vault protein integrates adhesion-driven signals to regulate collagen remodeling. | Cell Signal | 2024 | 39368789 | PubTator, text mining | PubMed |
| Retraction of: The cross-talk between DDR1 and STAT3 promotes the development of hepatocellular carcinoma. | Aging (Albany NY) | 2024 | 39288259 | PubTator, text mining | PubMed |
| DDR1 is a Novel Biomarker and Potential Therapeutic Target for the Combination Treatment of Liver Hepatocellular Carcinoma. | Cancer Control | 2024 | 39284684 | PubTator, text mining | PubMed |
| Analyzing the role of TM4SF1 expression in pancreatic adenocarcinoma: understanding prognostic implications and therapeutic opportunities. | J Gastrointest Oncol | 2024 | 39279979 | PubTator, text mining | PubMed |
| Functional Role of DDR1 in Oligodendrocyte Signaling Mechanism in Association with Myelination and Remyelination Process in the Central Nerve System. | J Physiol Investig | 2024 | 39175192 | PubTator, text mining | PubMed |
| Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer. | Biochim Biophys Acta Mol Basis Dis | 2024 | 39089636 | PubTator, text mining | PubMed |
| Retrosynthesis prediction with an iterative string editing model. | Nat Commun | 2024 | 39080274 | PubTator, text mining | PubMed |
| Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer. | J Drug Target | 2024 | 39072640 | PubTator, text mining | PubMed |
| DDR1 Drives Malignant Progression of Gastric Cancer by Suppressing HIF-1α Ubiquitination and Degradation. | Adv Sci (Weinh) | 2024 | 39024501 | PubTator, text mining | PubMed |
| Expression of the Discoidin Domain Receptor Family Depended on Glucose and Their High Expression in Arterial Tissues in the Rat Model of Type 2 Diabetes. | Biol Pharm Bull | 2024 | 39010214 | PubTator, text mining | PubMed |
| Large-scale whole-exome sequencing analyses identified protein-coding variants associated with immune-mediated diseases in 350,770 adults. | Nat Commun | 2024 | 39009607 | PubTator, text mining | PubMed |
| From pixels to druggable leads: A CADD strategy for the design and synthesis of potent DDR1 inhibitors. | Comput Methods Programs Biomed | 2024 | 38991374 | PubTator, text mining | PubMed |
| A highly selective inhibitor of discoidin domain receptor-1 (DDR1-IN-1) protects corneal epithelial cells from YAP/ACSL4-mediated ferroptosis in dry eye. | Br J Pharmacol | 2024 | 38978400 | PubTator, text mining | PubMed |
| Overcoming the Tumor Collagen Barriers: A Multistage Drug Delivery Strategy for DDR1-Mediated Resistant Colorectal Cancer Therapy. | Adv Sci (Weinh) | 2024 | 38953306 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/780/papers?page=9